MD | Oncology Resident at San Raffaele Hospital, Milan | Now based in Barcelona at IBCC | Part of the scientific team of MEDSIR
Joined February 2022
- Tweets 36
- Following 58
- Followers 38
- Likes 73
11 Photos and videos
Pinned Tweet
🧵 1/10
Do you know everything about Trop2? 🤔
In this pan-cancer multi-omic analysis, we explored TACSTD2 expression, regulation, and biological associations across normal tissues and tumor types.
🔗nature.com/articles/s41698-0…
1
12
18
2,013
🧵 1/10
Do you know everything about Trop2? 🤔
In this pan-cancer multi-omic analysis, we explored TACSTD2 expression, regulation, and biological associations across normal tissues and tumor types.
🔗nature.com/articles/s41698-0…
1
12
18
2,013
🧵10/10
This was truly a team effort.
Special thanks to my mentor @BianchiniGP , Barbara Galbardi, @giu_viale , @DugoMat , @GileadSciences for supporting this project through an unrestricted research grant, and @MyUniSR & @SanRaffaeleMI
Many thanks also to all co-authors! 👇
1
2
71
🙏🙏 @MatteoMNaldini , @CarloBoMD , @gdemicheli1 , @LLicata88 , @mariani_m97 , Marta Piras, @CarmenCriscit , Marco Barreca, @mauricallari , Caterina Zanibelli, Francesca PatanĂ©, @anto_chiavassa , JosĂ© Perez-GarcĂa, @HRazaAliLab , @JavierCortesMD , @lajos_pusztai and Luca Gianni
3
80
Giulia Notini retweeted
May 20
🔥 Who truly benefits from immune checkpoint inhibitors in early triple-negative breast cancer (#TNBC)?
Precision immunology is a major unmet need
âś…Key finding: on-treatment complement baseline biopsies
Immunity is dynamic, not a snapshot
Link and more 👇👇👇
@Annals_Oncology
May 20
đź“ŁNew work from the NeoTRIPaPDL1 trial led by @BianchiniGP out now in @Annals_Oncology!
We profiled tumor gene expression before AND during neoadjuvant chemo ± atezolizumab (ICI) in TNBC to find predictors of pCR: doi.org/10.1016/j.annonc.202…
Key findings👇 #TNBC #immunotherapy
3
33
74
14,837
Giulia Notini retweeted
đź“ŁDe-escalation strategies in HER2 EBC aim at reducing treatment toxicity without compromising efficacy
PHERGain-2 tested a pCR-guided de-escalation to omit CT in selected patients, and resulted in HRQoL preservation and pCR rate like standard CT HP
doi.org/10.1016/j.annonc.202…
29
60
5,264
My personal highlight from #EsmoBreast2026 (which I'll remember forever!).
Thank you @JavierCortesMD for being exactly who you are (including the Paul the Octopus substitute). Very lucky to learn from brilliant people who manage to make this job both inspiring and fun ❤️
2
68
ADCs are reshaping breast cancer care, but enthusiasm alone is not a strategy.
In our new @PLOSMedicine Perspective, with my mentors (the actual dream team), we dig into some of the big challenges in modern ADC development.
Thoughts? đź’
@BianchiniGP @JavierCortesMD
👇👇
2
7
2,815
Giulia Notini retweeted
Jan 19
A key topic of debate on early #breastcancer is how will the choice of adjuvant #CDKi, #PARPi and ChT change in the context of emerging de-escalation strategies for axillary surgery.
We discuss this in our work on Cancer Treatment Reviews.
cancertreatmentreviews.com/a…
@BianchiniGP
3
5
2,213
Giulia Notini retweeted
20 Oct 2025
Couldn’t be prouder of @MatteoMNaldini for receiving the ESMO Research Fellowship 2025! 🌟
You’ve worked incredibly hard and truly earned this.
Deep thanks to @myESMO for always believing in and supporting the next generation of physician-scientists.
1
6
47
4,647
Giulia Notini retweeted
30 Sep 2025
đź“ŁAnother step forward for #precision_immunotherapy in breast cancer!
🚀Just out in @Nature_NPJ Breast Cancer our exploratory analysis of the NeoTRIP trial showing the role of tumor-specific MHC-II as a predictor of immunotherapy benefit in #TNBC.
đź“Śrdcu.be/eIKAH
2
11
25
2,865
Giulia Notini retweeted
19 Dec 2024
🔥Impressed by PATINA trial results?
👉 the longest mPFS ever in breast cancer (44 mths)
Unexpected? Not really
- Our study (👇👇) explain the biological rational
- Supportive clinical trials (NA-PHER2, PERTAIN)
❗️CLEOPATRA trial did not allow ET maintenance
@SABCSSanAntonio
13 Mar 2022
📢Proud to see our work just published in @CCC_AACR. Resistance to drugs targeting ER (fulvestrant) and HER2 (trastuzumab /-pertuzumab) can be bypassed by co-targeting CDK4/6 (palbocilib), enhancing transition from quiescence to sustained senescence
👇👇
pubmed.ncbi.nlm.nih.gov/3525…
36
69
8,603
Giulia Notini retweeted
22 Jul 2024
Excited to share our latest publication on @JAMANetworkOpen : "Completion rate and positive results reporting among immunotherapy trials in breast cancer, 2004-2023.”
#BreastCancerResearch @OncoAlert @SanRaffaeleMI
👇Check out some key insights below
3
15
29
6,110